VJVirtual | MRx0518 combination therapy meets primary efficacy endpoint ahead of enrollment completion

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, shares promising interim results from the ongoing study (NCT03637803) of MRx0518 in combination with pembrolizumab, an anti-PD-1 checkpoint inhibitor, in patients with secondary resistance to pembrolizumab. Part A of the study has been completed with a strong safety profile, evidence of clinical benefit and durable responses in patients. Interim results from part B of the study, investigating clinical benefit, have met the primary endpoint criteria with 4 of 16 evaluable patients of the metastatic renal cell carcinoma (mRCC) cohort demonstrating significant clinical benefits prior to enrollment completion. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).